Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With Hypoparathyroidism

Benzinga Newsdesk www.benzinga.com Positive 94.5%

Neg 0% Neu 0% Pos 94.5%

Multi-organ system and quality-of-life benefits sustained through three and a half years
86% response rate for the multi-component endpoint
89% of patients completed the three-and-a-half-year trial

Comments

No comments yet. Be the first!